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Mouse models of metastasis: progress and prospects
Laura Gómez-Cuadrado1,*, Natasha Tracey1,*, Ruoyu Ma2, Binzhi Qian2,3 and Valerie G. Brunton1,‡
ABSTRACT
Metastasis is the spread of cancer cells from a primary tumor to
distant sites within the body to establish secondary tumors. Although
this is an inefficient process, the consequences are devastating as
metastatic disease accounts for >90% of cancer-related deaths. The
formation of metastases is the result of a series of events that allow
cancer cells to escape from the primary site, survive in the lymphatic
system or blood vessels, extravasate and grow at distant sites. The
metastatic capacity of a tumor is determined by genetic and epigenetic
changeswithin the cancer cells aswell as contributions fromcells in the
tumor microenvironment. Mouse models have proven to be an
important tool for unraveling the complex interactions involved in the
metastatic cascade and delineating its many stages. Here, we critically
appraise the strengths and weaknesses of the current mouse models
and highlight the recent advances that have been made using these
models in our understanding of metastasis. We also discuss the use of
these models for testing potential therapies and the challenges
associated with the translation of these findings into the provision of
new and effective treatments for cancer patients.
KEY WORDS: Cancer, Metastasis, Mouse models, Stroma
Introduction
Metastasis, the process of tumor cell migration from the primary site
to distant organs, remains the major cause of cancer-related deaths,
despite therapeutic advances in recent years (Steeg, 2016). This
highlights the urgent need to better understand the mechanisms that
underlie metastasis and to identify new therapeutic strategies and
drug targets to treat metastatic disease. A number of excellent
review articles have covered the exciting new advances in our
understanding of the genetic and molecular events that govern
metastatic spread (Lambert et al., 2017; Massagué and Obenauf,
2016; Sethi and Kang, 2011; Turajlic and Swanton, 2016; Valastyan
and Weinberg, 2011), which will not be covered in detail here. In
this Review, we discuss the different mouse models of metastasis
that are currently used, and focus on how they have contributed to
the field thus far. We consider their strengths and weaknesses and
the technological advances that are driving the development of more
refined models, which have the potential to impact on the translation
and development of better therapeutic interventions. We first
provide an overview of the metastatic process.
The metastatic cascade
Metastasis is a multistep process, as illustrated in Fig. 1. The first
step of the metastatic cascade is local invasion at the primary tumor
site. This process is initiated by the activation of signaling pathways
that regulate cytoskeletal dynamics, loss of adhesion amongst tumor
cells and turnover of the surrounding extracellular matrix (ECM)
(Friedl and Alexander, 2011). This allows the tumor cells to migrate
away from the primary tumor and infiltrate into surrounding tissues.
To initiate the spread to secondary sites, the tumor cells must then
intravasate (see Glossary, Box 1) into the blood circulation or
lymphatic system. Dispersal of tumor cells in the lymphatic system
leads to lymph node metastasis in the first instance, while distal
metastasis usually requires tumor cells to disseminate via the blood
circulation (hematogenous) with the choice of a tumor cell to use
either lymphatic or hematogenous dissemination, governed by a
number of factors (Chiang et al., 2016; Wong and Hynes, 2006). In
this article, we will focus on hematogenous metastasis.
After entry into the circulation, tumor cells can disseminate
widely throughout the body and are known as circulating tumor cells
(CTCs) (see Glossary, Box 1). CTCs have the potential to serve as
prognostic markers of metastasis and survival, as has been discussed
extensively in recent reviews (Alix-Panabieres̀ and Pantel, 2013;
Plaks et al., 2013). On reaching distal organs, surviving tumor cells
can be intercepted in small capillaries or actively adhere to larger
blood vessels and extravasate through paracellular or transcellular
transendothelial migration (see Glossary, Box 1) (Reymond et al.,
2013), prior to colonization (see Glossary, Box 1). This process can
be promoted by alterations induced by secreted factors and
extracellular vesicles derived from the primary tumor, before the
establishment of metastases (McAllister and Weinberg, 2014).
These alterations involve fibroblasts, endothelial cells and immune
cells, especially bone marrow-derived immature myeloid cells,
which can collectively establish a pre-metastatic niche (Box 2) that
provides an environment favoring the recruitment of CTCs and their
subsequent growth (Liu and Cao, 2016; Peinado et al., 2017).
Once settled in the metastatic organ, tumor cells are referred to as
disseminated tumor cells (DTCs) (see Glossary, Box 1). DTCs can
be present for years or decades and stay in a latent state as single
cells or micrometastases (Massagué and Obenauf, 2016). This
tumor dormancy may result from single DTCs entering a quiescent
state or may be due to inadequate vascularization or immune
clearance of micrometastases (Gay and Malanchi, 2017).
Eventually, clinically relevant macrometastases (see Glossary,
Box 1) arise from the outgrowth of DTCs, a process termed
colonization (see Glossary, Box 1).
Models of metastasis
In this section, we provide an overview of the main mouse models of
metastatic cancer that are currently in use, from mice generated
using transplantable cancer cells and tumors to genetically
engineered mouse models (GEMMS) (see Glossary, Box 1)
(Francia et al., 2011; Kabeer et al., 2016; Kersten et al., 2016;
Saxena and Christofori, 2013). These mouse models are classified
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and summarized in Table 1, and examples of models that have been
used are listed in Table 2.
Transplantation models
Spontaneous models of metastasis
Spontaneous metastasis models allow the spread of cells from a
primary tumor to secondary sites to be followed in animals that have
received ectopic or orthotopic (see Glossary, Box 1) transplants of
cancer cells or tissue. The advantage of these models is that they
allow the entire metastatic cascade to be modeled. However,
although ectopic subcutaneous transplantation of multiple cell or
tumor types is widely used to monitor tumor growth as it induces
rapid tumor growth in the highly vascularized skin, and tumor
development can be monitored easily through the use of caliper
measurements, metastasis is not often seen in these models and
tends to be restricted to allograft models (see below) such as the B16
melanoma and Lewis lung carcinoma model (Table 2). Orthotopic
studies are able to better recapitulate human cancers by enabling
interactions with the tissue of origin, which can impact on the initial
invasion and intravasation and may reflect the increased metastatic
spread seen in orthotopic models (Francia et al., 2011; Kellar et al.,
2015) (Table 2). This is dependent on the ability to implant tumor
cells in the orthotopic site from which the original tumor was
derived, which has been successful for a number of tumor types
including mammary, pancreatic, lung and colon (Table 2). In some
models, there is a long latency, and resection of the primary tumor is
needed to allow development of metastases; this is only possible for
certain cancers, such as mammary tumors and melanoma (Coffelt
et al., 2015; Cruz-Munoz et al., 2008). However, models in which
resection of the primary tumor is possible have the benefit of
allowing potential adjuvant therapies to be tested.
Experimental models of metastasis
Experimental models of metastasis are used to evaluate the capacity
of cancer cells to arrest, extravasate and grow in particular organs in
ectopic sites following intravascular injection. Different sites of
vascular injection in the mouse, including the lateral tail vein, intra-
portal, intra-carotid and intra-cardiac, define the site of colonization
(reviewed in Khanna and Hunter, 2005). For example, injection into
the tail vein leads to the formation of lung metastases, which reflects
the rapid trapping of cells within the microvasculature of the lung
minutes after injection. Intra-cardiac injection allows wider
dissemination of cancer cells and is commonly used to model
bone and brain metastasis. Other models include intra-peritoneal
injection to model the local dissemination of ovarian cancer or intra-
splenic injection of colon cancer cells leading to metastasis
formation within the liver. A drawback of experimental metastasis
models is that they do not recapitulate the first steps of the metastatic
cascade, and only reflect homing of tumor cells circulating in the
bloodstream to a limited set of secondary organs. Despite this, they
have been instrumental in elucidation of tumor-host interactions
required for the initial arrest and colonization at metastatic sites, as
discussed below.
Both allograft and xenograft (see Glossary, Box 1) transplantation
models are used in spontaneous and experimental metastasis assays
and the characteristics of these models are explained in further detail
below.
Allografts
Allograft transplantation models are generated by the transplantation
of mouse-derived cancer cells and tumors into mice. The use of
genetically identical syngeneic (see Glossary, Box 1) models, to
prevent graft versus host reactions, allows investigation of the
immune system in cancer progression and identification of new
therapeutic opportunities (Serrels et al., 2015).
Fidler (1973) described the first syngeneic mouse model of
metastasis and provided the first demonstration that the metastatic
potential of tumor cells could be enhanced through in vivo selection.
B16 melanoma tumor cells are derived from a spontaneous
melanoma that developed in the common C57BL/6 strain of
laboratory mice. B16 cells with enhanced metastatic properties were
generated after several rounds of in vivo selection by subcutaneous
injection of melanoma cancer cells into the syngeneic C57BL/6J
mouse. The occurrence of metastasis to the lungs increases
significantly with the clonally selected tumor lines derived from
successive pulmonary metastases (Fidler, 1973).
Xenografts
In contrast to allograft models, xenografts involve human cancer
cells and tumors. Human tissue must be introduced into
Primary tumor 
Intravasation 
Extravasation 
Target organ 
Circulation 
Micrometastasis Colonization 
Pre-metastatic niche 
Invasion 
ECM Exosome 
Platelet Basement 
membrane 
Tumor cell Cytokines 
Blood vessels Epithelial cell 
Endothelial cell 
Key
Fig. 1. Metastatic cascade. Metastasis is a multistep
process. Initially, tumor cells migrate into adjacent tissues,
referred to as local invasion. This involves breakdown of the
basement membrane and invasion into the surrounding
ECM. Intravasation then allows cells to enter the circulation.
In blood vessels, CTCs exist as single cells or clusters,
coated with platelets. They need to survive shear stress
and evade clearance by the immune system to successfully
reach distant organs. Tumor cells then attach to endothelial
cells, which facilitates their extravasation. After settling in
the metastatic target organ, tumor cells must survive in this
foreign environment and establish micrometastases.
These DTCs can remain dormant for many years before
proliferating into large macrometastases in a process
termed colonization. The primary site also regulates the
development of metastasis via secretion of factors (such as
cytokines and exosomes) that can prime a pre-metastatic
niche (Box 2) and support survival of DTCs. See Glossary
in Box 1 for an explanation of key terms.
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immunocompromised (see Glossary, Box 1) or immune-deficient
mice in order to prevent rejection by the host. An advantage of these
tumormodels is that the donor cells are human in origin; however, the
key drawback is lack of the host adaptive immune system, which is
now recognized to contribute to many aspects of primary tumor
growth andmetastatic spread (Hanahan andWeinberg, 2011). The use
of xenograft mouse models in metastatic studies has been restricted to
studies in which highly metastatic variants have been derived through
in vivo selection (e.g.MDA-MB-231 breast cancer cells, KM12 colon
carcinoma cells and WM239Amelanoma cells), which overcome the
problemof limitedmetastatic potential (Table 2). Thismethod has also
been used extensively to identify gene expression signatures that
regulate organ-specific patterns of breast cancer metastasis (Bos et al.,
2009; Kang et al., 2003; Minn et al., 2005).
Cancer cell lines often fail to retain the characteristics of the
original tumor when cultured in vitro. Therefore, they do not reflect
the phenotypic and genetic heterogeneity of human cancers and,
consequently, xenograft models are poor predictors of clinical
responses (Kersten et al., 2016). Patient-derived xenografts (PDXs)
(see Glossary, Box 1) have emerged as a potential solution to this
problem (reviewed inWhittle et al., 2015). PDXs are generated from
resected tumors, propagated directly in immunocompromised mice
following orthotopic or subcutaneous injection, avoiding in vitro
selection pressures. PDXs have been shown to reflect the diversity
of human cancer, recapitulating the histology and the metastatic
characteristics of the original tumor (DeRose et al., 2011; Eyre et al.,
2016; Hiroshima et al., 2016; Julien et al., 2012; Puig et al., 2013).
Other studies show that the site and frequency of PDX metastasis
may vary from that seen in the patient and the engraftment rate is
relatively low. Furthermore, the lack of an intact immune system and
the presence of mouse stroma mean that PDXs are not an ideal
model for studying the role of the tumor microenvironment in
disease progression (Jackson and Thomas, 2017; Pompili et al.,
2016; Whittle et al., 2015). To overcome these limitations,
humanized xenograft mouse models are being developed, in
which the human components of the tumor microenvironment,
such as immune cells, peripheral blood and stromal tissue have been
engrafted (Bankert et al., 2011; Cassidy et al., 2015; Kuperwasser
et al., 2005; Morton et al., 2016). There are also challenges
associated with these mice, however, including the technical
difficulty of increasing the spectrum of immune cells engrafted
while reducing the mouse innate immune response (Shultz et al.,
2012). The impact that these humanized mouse models will have on
research into metastasis remains unclear at present.
Genetically engineered mouse models
Genetically engineered mouse models (GEMMs) (see Glossary,
Box 1) display de novo tumor progression and metastasis formation,
usually in an immune-competent tumor microenvironment. This
enables both the tumor cell-autonomous and stromal influences on
Box 1. Glossary
Allograft: The transplant of cells or organs from one individual to another individual of the same species.
Cancer-associated fibroblast (CAF): Fibroblasts found within or in close proximity to a tumor. Usually derived from normal fibroblasts but can also be
formed from pericytes (contractile cells that line capillaries) and smooth muscle cells, among other cell types.
Circulating tumor cell (CTC): Tumor cells that have left the primary tumor and entered the circulatory system.
Colonization: The processes (e.g. survival and proliferation) which allow disseminated tumor cells to form large macrometastases.
Cre recombinase/loxP : Cre recombinase enzymatically removes sequences that are flanked (floxed) by inserted loxP sequences.
CRISPR/Cas9: Gene-editing technology that enables precise genomic modifications. This technology can be used to generate gene modifications,
deletions and insertions, by using a synthetic guide RNA to introduce a double-strand break at specific sites in DNA, mediated by Cas9 endonuclease.
Disseminated tumor cell (DTC): Tumor cells that have settled in distant organs away from the primary tumor site after exiting the circulatory system.
Ectopic: The transplantation of a cell type to a location in which it is not found under normal physiological circumstances.
Epithelial-to-mesenchymal transition (EMT): Loss of cell-cell adhesion complexes and cell polarity by an epithelial cell, and the gain of an invasive,
migratory, mesenchymal phenotype.
Exosome: Extracellular vesicles that are released from cells after the fusion of multivesicular bodies with the plasma membrane.
Extracellular matrix (ECM): The acellular support surrounding tissues.
Extravasation: The process by which a tumor cell leaves the circulatory system and enters a secondary site away from the primary tumor.
Genetically engineeredmousemodel (GEMM): Amousewith a genome altered by genetic engineering techniques, including gene deletion, mutation or
addition. This can be performed in a tissue- or cell-specific manner and may also be inducible.
Immunocompromised mice: Mice in which specific elements of the immune system have been removed to allow engraftment of human material.
Integrin: Transmembrane receptor protein that cells use to adhere and respond to the extracellular matrix.
Intravasation: The process by which a tumor cell leaves the primary tumor and enters the circulation.
Invadopodium: Actin-rich protrusion present at the membrane of invasive cancer cells that extends and degrades the extracellular matrix.
Micrometastasis: Small clusters of cancer cells in secondary organs that are too small to detect through screening.
Organoids (tumor): three-dimensional cultures of tumor cells.
Orthotopic: The transplantation of a cell type or organ to a location in which it would be found under normal physiological circumstances.
Patient-derived xenograft (PDX): A model in which human patient tumor material is implanted into an immunocompromised host, most commonly the
mouse.
Seeding: In the context of metastasis, seeding refers to the process whereby tumor cells ‘seed’ new tumors in distant organs. Originally described in
Stephen Paget’s ‘seed and soil’ hypothesis of cancer metastasis (Paget, 1989). The seeding process includes tumor cell adherence to the blood vessel in
the distal organ, extravasation, migration to the tissue parenchyma, and survival.
Syngeneic: In transplantation biology, this refers to individuals or tissues that are genetically identical or closely related, allowing the transplantation of
tissues from the strain of origin into immunocompetent mice.
Transendothelial migration: Movement of tumor cells through the endothelial barrier either paracellularly (through the endothelial cell junctions) or
transcellularly (through the endothelial cell body).
Tumor-associated macrophage (TAM): A macrophage found within or in close proximity to a tumor that actively promotes tumor growth through the
secretion of cytokines and chemokines.
Tumor microenvironment: All elements that make up the surroundings of the tumor, including other cell types, vasculature and the extracellular matrix.
Xenograft: The transplant of cells or organs from one species into an individual of a different species.
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all stages of the metastatic cascade to be modeled, making GEMMs
an invaluable resource for studying metastasis. Their use in cancer
research has been widely reviewed (Kabeer et al., 2016; Kersten
et al., 2016; Saxena and Christofori, 2013). Here, we provide an
overview of the models available and discuss their potential for
modeling metastatic disease.
The first transgenic models used tissue-specific promoters, such as
the mammary-specific MMTV promoter, to drive expression of
oncogenes such as v-ErbB2 and v-HRas (Muller et al., 1988; Sinn
et al., 1987). This was followed by the generation of tumor suppressor
gene knockout mice (e.g. Trp53) that have a predisposition to tumor
formation (Donehower et al., 1992). Although these models have
given insight into many fundamental aspects of cancer biology, it is
difficult to model sporadic cancer development seen in humans due
to lack of tissue specificity of gene knockouts and control of
transgene expression in specific cell lineages (Kersten et al., 2016).
More advanced models allow conditional activation of
oncogenes and/or inactivation of tumor suppressor genes in
somatic cells. The Cre recombinase/loxP system (see Glossary,
Box 1) is used widely for this. Using this system, genes that are
flanked by loxP recombination sites are deleted following activation
of Cre recombinase (Gu et al., 1993). Use of tissue-specific
promoters to drive Cre recombinase expression, combined with
expression of oncogenes that are known to be associated with
development of human tumors in those tissues, has resulted in the
generation of models that recapitulate many of the molecular
characteristics and histopathological features of the human disease
(Hingorani et al., 2003; Holen et al., 2017; Jackson et al., 2001;
Shibata et al., 1997). These have been invaluable in dissecting the
complexities of human cancer and its progression.
Further control can be achieved by using regulatable systems such as
the Cre-ER system, in which the hormone-binding domain of the
estrogen receptor (ER) is fused to Cre recombinase: treatment of mice
with the estrogen analogue tamoxifen leads to activation of Cre
recombinase in a temporal manner (Lewandoski, 2001). The
tetracycline-inducible system also permits the switching on or off
(Tet-On/Tet-Off system) of a specific gene of interest in a tissue- and
time-specificmanner following administration ofdoxycyline (Gunther
et al., 2002). This temporal and spatial control of gene activation and
inactivation is useful for overcoming unwanted effects that could
impact on organ-specific development or result in embryonic lethality,
as seen upon deletion of the Rb1 tumor suppressor (Lee et al., 1992).
These models can also be used to address the importance of genetic
changes at specific times during tumor progression.
An important limitation of GEMMs is the low incidence of
metastatic spread that often does not reflect the organ tropism seen
in the human disease (Kabeer et al., 2016; Kersten et al., 2016).
Although identification of the most appropriate tissue-specific
Box 2. Pre-metastatic niche
Pre-metastatic niches are organ-specific supportive biological
environments that support survival of CTCs in distal organs and
promote metastatic outgrowth. The formation of the pre-metastatic
niche is governed by secreted factors from the primary tumor, including
growth factors and inflammatory cytokines and chemokines. Recent
studies found that tumor-derived exosomes can also promote niche
establishment and determine organ specificity in some types of cancer;
however, whether it is a common feature for pre-metastatic niche
formation remains unclear. These tumor-derived secreted factors induce
changes in distant pre-metastatic sites while also mobilizing bone
marrow-derived cells, the recruitment of which – along with a number of
other types of immune cell – to the niche leads to remodeling of the local
environment and formation of the pre-metastatic niche. This involves
interactions with local resident stromal cells, such as endothelial cells,
macrophages and fibroblasts, and also the extracellular matrix, which all
cooperate to form a permissive environment for tumor outgrowth. For
example, activated fibroblasts remodel the ECM by secreting matrix
components such as fibronectin andmetalloproteinases that break down
existing ECM. Increased fibronectin in the niche enhances adhesion of
recruited bone marrow-derived cells. Lysyl oxidase, an enzyme that
cross-links collagen and elastins in the ECM, is also important in the
formation of the pre-metastatic niche; by remodeling the ECM, this
enzyme enhances myeloid cell infiltration. For further information,
readers are directed to two reviews on the formation and role of the
pre-metastatic niche (Liu and Cao, 2016; Peinado et al., 2017).
Table 1. Strengths and weaknesses of mouse models of metastasis
Type of model Strengths Weaknesses
Tumor transplantation:
spontaneous metastasis
Metastatic disease development from primary tumor
site mimics human disease progression
Models all stages of the metastatic cascade
Immunocompetent host if allograft
Low cost
Mouse microenvironment
Applicable to limited number of cell lines
Poor tropism of metastasis in reference to the clinical setting
Asynchronous metastatic development
Removal of primary tumor to allow development of metastases can be
performed only on certain tumor types such as breast, prostate, pancreas
and ectopic transplants
Immunocompromised host if xenograft
Tumor transplantation:
experimental metastasis
Rapid and reproducible development of metastases
Site-specific development of metastases
Applicable to a wide number of cell lines and tumor
models
Immunocompetent host if allograft
Low cost
Mouse microenvironment
Only models late stages of the metastatic cascade
Immunocompromised host if xenograft
GEMM Metastatic spread of spontaneous de novo tumors,
mimicking human disease
Tumors develop in natural microenvironment
Tumors display genetic heterogeneity
Tumors resemble the molecular and
histopathological characteristics of the
human disease
Models have the potential to model all stages of the
metastatic cascade
Immunocompetent host
Mouse rather than human microenvironment
Genetics (promoter and oncogenes) often not truly representative of the
human disease
Promoters not well defined to a specific lineage
Can have low penetrance and long latency of metastatic disease
development
Poor tropism of metastasis in reference to the clinical setting
Extensive breeding programs often required (cost and time implications)
Asynchronous metastatic development
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promoters and the correct combination of genetic alterations has
provided more representative models (Derksen et al., 2006;
Hingorani et al., 2003), tumor spread to some metastatic sites
has been more difficult to model. For example, it has been
challenging to model the development of bone metastases, a
common site of secondary lesions in prostate and breast cancer
(Rampetsreiter et al., 2011). A second drawback of GEMMs is
that in many cases the long latency requires mice to be sacrificed
due to primary tumor burden before metastatic lesions have
developed. This can be overcome by removal of the primary
tumor, after which the subsequent development of metastases can
be monitored (Coffelt et al., 2015; Doornebal et al., 2013).
Applications of mouse models in metastatic research
Despite the limitations discussed above, mouse models have made
important contributions to our understanding of cancer progression
Table 2. Examples of commonly used models of metastasis
Classification
Tumor
type
Cells/tumors transplanted in mice or
genotypic details of GEMM strain Site of metastasis References
Spontaneous metastasis
Allograft, orthotopic Melanoma Mouse B16 cells (C57BL/6 mice) Lungs (Fidler, 1973)
Allograft, orthotopic Mammary Mouse K14Cre; Cdh1F/F; Trp53F/F (KEP)
cell line and tumor fragments
(FVB mice)
Lungs, lymph nodes, liver, spleen,
gastrointestinal and urogenital tract,
pancreas, mesenterium and peritoneum
(Coffelt et al., 2015; Derksen
et al., 2006; Doornebal
et al., 2013)
Mouse 4T1 cells (BALB/c mice) Lungs and liver (Aslakson and Miller, 1992)
Allograft, ectopic
(subcutaneous)
Lung Mouse Lewis lung carcinoma (LLC1)
cells (C57B1 mice)
Lungs (Bertram and Janik, 1980)
Xenograft, orthotopic Mammary Human MDA-MB-231 cells
(NOD/SCID mice)
Lungs, liver, lymph nodes (Munoz et al., 2006)
Human SUM1315 cells (NOD/SCID
mice)
Lung and human bone implant (Kuperwasser et al., 2005)
Xenograft, orthotopic Colon Human HCT116, SW-620, DLD-1 cells
(Swiss Nu/Nu)
Peritoneum, diaphragm, lymph nodes,
pancreas, liver and lungs
(Céspedes et al., 2007)
Xenograft, orthotopic Melanoma Human 113/6-4Lmelanomacells derived
from WM239A (CB17-SCID mice)
Central nervous system (Cruz-Munoz et al., 2008)
PDXs, orthotopic Mammary Primary breast tumors and metastases
[NOD/SCID mice and NOD/SCID
Il2rg−/− (NSG) mice]
Lung, lymph nodes, peritoneum (DeRose et al., 2011)
PDXs, ectopic
(subcutaneous)
Mammary Primary breast tumors and metastases
[NOD/SCID Il2rg−/− (NSG) mice)]
Lung (Eyre et al., 2016)
PDXs, orthotopic Cervical Primary HER2-expressing cervical tumor
(athymic nu/nu nude mice)
Lung, lymph nodes, peritoneum, liver (Hiroshima et al., 2016)
PDXs, orthotopic Colon Primary colorectal tumors and liver
metastases (NOD/SCID mice)
Liver, lung, abdominal cavity (Puig et al., 2013)
PDXs, ectopic
(subcutaneous) and
orthotopic
Colon Primary colorectal tumors, peritoneal
carcinoses and metastases (Swiss
nude and CB17-SCID mice)
Hepatic, splenic, and mesenteric
lymph node
(Julien et al., 2012)
PDXs, ectopic
(intraperitoneal)
Ovarian Primary ovarian tumors [NOD/SCID
Il2rcnull (NSG) mice]
Lung (Bankert et al., 2011)
Experimental metastasis
Intra-venous Mammary Human MDA-MB-231 cells Lung (Minn et al., 2005)
Mammary Mouse Met-1 cells Lung (Qian et al., 2011)
Melanoma Human A7 and mouse B16 cells Lung (Gil-Bernabe et al., 2012)
Melanoma Mouse B16 cells Lung (Hiratsuka et al., 2002, 2006;
Kaplan et al., 2005)
(Hiratsuka et al., 2002, 2006;
Kaplan et al., 2005)
Lung Mouse Lewis lung carcinoma
(LLC) cells
Lung
Intra-cardiac Mammary Human MDA-MB-231 cells Brain (Bos et al., 2009)
Mammary Human MDA-MB-231 cells Bone (Kang et al., 2003)
Prostate Mouse RM1 cells Bone (Jung et al., 2013)
Intra-iliac artery Mammary Human MDA-MB-231, MCF-7,
MDA-MB-361 cells
Bone (Wang et al., 2015)
Intra-splenic Colon Human KM12 cells Lymph nodes and liver (Morikawa et al., 1988)
Intra-tibial Prostate Human PC-3 cells Bone (Fisher et al., 2002)
Intra-peritoneal Ovary Human SKOV3 and ES2 cells +/−
adipose-derived mesenchymal stem
cells derived from omentum
Mesentery (Chu et al., 2015)
GEMM
Spontaneous metastasis Mammary MMTV-PyMT Lungs and lymph nodes (Guy et al., 1992)
Spontaneous metastasis Mammary MMTV-Erbb2 Lungs and lymph nodes (Muller et al., 1988)
Conditional, Cre-loxP Pancreatic KPC [Lox-Stop-Lox (LSL)-KrasG12D;
LSL-Trp53R172H; Pdx1-Cre] model
Liver, lung, pleural nodules and
peripancreatic lymph node
(Hingorani et al., 2005)
Conditional, Cre-loxP
and Flp-FRT
Pancreatic R26CAG-CreERT2; FSF-R26CAG-CreERT2 Liver and lungs (Schönhuber et al., 2014)
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and metastasis. Here, we highlight some recent advances in which
mouse models have been instrumental in defining the key drivers
and features of metastatic cancer. We also outline the usefulness of
these models as preclinical drug development tools.
Stromal cell interactions at the primary tumor site
In vivo metastasis models are important tools to investigate the
interaction of tumor cells with tumor-associated stromal
components. Within this complex microenvironment, several
immune cell populations have been shown to promote tumor
invasion and metastasis (Fig. 2) and GEMMs and syngeneic
models, both of which have intact immune systems, have provided
many valuable insights into how the immune system regulates
metastatic progression. Macrophages are often the most abundant
infiltrating immune cells in the tumor. These tumor-associated
macrophages (TAMs) (see Glossary, Box 1) play multiple roles in
promoting cancer metastasis and are associated with metastasis and
poor prognosis (Kitamura et al., 2015; Qian and Pollard, 2010).
Intra-vital imaging studies have proven useful in elucidating the
complex role of TAMs. In a spontaneous GEMM of mammary
cancer, MMTV-PyMT (Table 2), cancer cells invade surrounding
tissues together with TAMs (Wyckoff, 2004). In this process, TAMs
secrete epidermal growth factor (EGF) to activate the EGF receptor
on cancer cells, and enhance their motility and invasive potential by
increasing invadopodium formation and ECM degradation (Zhou
et al., 2014). Reciprocally, tumor cells produce colony-stimulating
factor 1 (CSF1) to recruit and activate TAMs. Ablation of this
paracrine signal loop significantly inhibited tumor cell invasion in
MMTV-PyMT tumors and subsequent lung metastasis without
affecting primary tumor growth (Wang et al., 2009). Intra-vital
imaging ofMMTV-PyMT tumors has also illustrated that tumor cell
intravasation occurs in association with perivascular TAMs
(Wyckoff et al., 2007). Via direct interactions, invasive tumor
cells, perivascular macrophages and endothelial cells form
micro-anatomic structures within the tumor (termed ‘tumor
microenvironment for metastasis’ or ‘TMEM’) (Pignatelli et al.,
2014). The frequency with which these TMEMs occur has been
shown to predicate metastasis of ER+ breast cancer in a case-control
study with >3700 patient samples (Rohan et al., 2014). These
TMEM structures control tumor cell intravasation by transiently
increasing local vascular permeability in a vascular endothelial
growth factor (VEGF)-dependent manner, as illustrated by recent
studies using high-resolution two-photon intra-vital microscopy
(Harney et al., 2015). These data strongly indicate that the local
tumor microenvironment and macrophage interactions play a central
role in promotion of tumor cell intravasation, and highlight the
importance of using intra-vital microscopy to visualize these
processes.
Neutrophils have also been shown to contribute to invasion and
metastasis. Using a combination of GEMM and transplant models
of melanoma, UV radiation was shown to promote neutrophil
infiltration through secretion of high-mobility group protein B1
(HMGB1) derived from UV-damaged keratinocytes. This
neutrophil recruitment led to enhanced tumor migration and
invasion resulting in distal metastasis (Bald et al., 2014). More
recently, a role for neutrophils in the pre-metastatic niche within the
lung was established using the MMTV-PyMT model (Wculek and
Malanchi, 2015). This was mediated through secretion of
leukotrienes from neutrophils in the pre-metastatic niche, which
promoted metastatic formation. In the KPC (Lox-Stop-Lox (LSL)-
KrasG12D; LSL-Trp53R172H; Pdx1-Cre) GEMM of pancreatic
cancer, where mutations in Kras and Trp53 drive the development
of spontaneous pancreatic ductal adenocarcinomas (Gopinathan
et al., 2015), neutrophils have also been shown to promote
metastasis (Steele et al., 2016).
Among adaptive immune cells, Th2 cells, CD4+ T helper cells
expressing Type 2 cytokines [e.g. interleukin (IL) 4, IL10], have
been shown to promote tumor progression via activation of humoral
immunity and inflammation (Shurin et al., 1999). Using the
MMTV-PyMT model, it was found that CD4+ T helper cells can
induce alternative activation of TAMs and secretion of EGF, to
directly promote tumor invasion and egress from the primary tumor
as a result of IL4 activation (DeNardo et al., 2009). By utilizing
existing and emerging mouse models, future experiments could
uncover the role of other lymphocyte populations in tumor
progression and invasion.
Coffelt et al. (2015) used a GEMM of invasive lobular breast
cancer, the K14Cre; Cdh1F/F; Trp53F/F (KEP) model, and
transplanted tumor fragments from this KEP model into recipient
mice. Metastatic development was monitored following resection of
the primary tumor, and the authors observed that systemic
expansion of neutrophils significantly promoted spontaneous
metastasis to the lungs and lymph nodes by suppressing a CD8+
T cell-mediated anti-tumor immune response (Coffelt et al., 2015).
Mechanistically, this involves IL17 expression from γδ T cells that
leads to expansion of neutrophils via granulocyte colony stimulating
factor (G-CSF). IL17 derived from a subset of CD4+ T helper cells
has also been shown to promote anti-tumor immune responses
through the recruitment of dendritic cells and cytotoxic cells in
several murine tumor models (reviewed in Zou and Restifo, 2010).
Thus, the role of IL17 in metastasis may be dependent on the cancer
type and/or specific tissue environment.
Cells of mesenchymal origin, most notably mesenchymal stem
cells (MSCs) and cancer-associated fibroblasts (CAFs) (see
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CD4+ T cell 
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MSC 
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Fig. 2. Stromal influences in the primary tumor. Stromal cells such as
MSCs, fibroblasts and myeloid cells (including monocytes, macrophages and
neutrophils) promote metastasis and modulate the tumor microenvironment.
MSCs remodel the ECM and support invasion. Macrophages can promote
tumor invasion via several paracrine signaling factors. For example, in
response to tumor cell-derived CSF1, TAMs secrete EGF, which is permissive
for tumor cell invasion and migration. A subset of CD4+ T cells contributes to
tumor progression, while CD8+ T cells mainly mediate anti-tumor immune
responses. During intravasation, perivascular macrophages interact with
tumor cells directly to help subsequent tumor cells to transit the endothelial
barrier and initiate the journey of metastatic dissemination. See Glossary in
Box 1 for an explanation of key terms.
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Glossary, Box 1) can also promote metastasis through direct
interaction with tumor cells. For example, MSCs have been shown
to promote peritoneal dissemination of ovarian cancer cells via
activation of the matrix metalloproteinases (MMPs) MMP2 and
MMP9 (Chu et al., 2015). In xenograft and allograft models of
prostate cancer, chemokine (C-X-C motif ) ligand 16 (CXCL16)/
CXC receptor 6 (CXCR6) chemokine signaling promotes
recruitment of bone marrow-derived MSCs and their
differentiation into CAFs, which in turn promote prostate tumor
cell invasion and metastasis through production of chemokines such
as CXCL12 (Jung et al., 2013; Mognetti et al., 2013) and
chemokine (C-C motif ) ligand 5 (CCL5) (Luo et al., 2015). CAF-
derived MMPs can promote ECM remodeling and tumor cell
invasion (Kalluri and Zeisberg, 2006), and in an orthotopic model
of colon cancer, CAFs promote formation of distal metastases
through secretion of the glycoprotein stanniocalcin 1 (STC1) which
regulates intravasation of the tumor cells (Pena et al., 2013). CAFs
can also generate mechanical pressure and paracrine signaling to
promote tumor invasion and metastasis (Karagiannis et al., 2012),
and through remodeling of the ECM (Kaushik et al., 2016).
In summary, in vivo metastasis models have provided important
insights into the interactions of tumor and stromal cells that
contribute significantly to tumor invasion and metastasis. Of note,
only a minority of cancer cells are migratory, as revealed by intra-
vital imaging studies across multiple tumor models, even in
aggressive tumors (Condeelis et al., 2005; Scheele et al., 2016).
Thus, specific interactions of the tumor microenvironment with
these migratory tumor cells could be attractive targets to treat
metastatic disease.
Systemic influence on metastasis
The metastatic process is not only influenced by cell-cell
interactions within the adjacent primary tumor microenvironment
but also systemic alterations induced by the presence of tumor cells.
Experimental metastasis assays in tumor-bearing animals have been
key in demonstrating that primary tumor-derived systemic factors,
such as cytokines and immune cell chemoattractants, can alter
metastatic target tissues and influence the subsequent seeding (see
Glossary, Box 1) of tumor cells in these tissues (Hiratsuka et al.,
2002, 2006; Kaplan et al., 2005). More recently, elegant mouse
experiments again using experimental metastasis models have
shown that tumor-derived exosomes (see Glossary, Box 1) induce
pro-metastatic progenitor cells in the bone marrow through receptor
tyrosine kinase MET signaling (Peinado et al., 2012), and that
exosomal integrins (see Glossary, Box 1) can direct organ-specific
colonization by priming the metastatic niche (Box 2) (Hoshino
et al., 2015). Such advances will impact on how we can harness the
ability to measure specific systemic factors in clinical samples to
allow more careful monitoring of tumor progression.
Systemic influences can also promote colonization after metastatic
seeding. For example, a study using an esophageal cancer model
showed that lung metastatic colonization (following tail vein
injection of tumor cells) can be significantly promoted by distal
tumors in an insulin growth factor (IGF)-II-dependent manner (Li
et al., 2014). Using a xenograft model in which human breast cancer
cell lines with different tumorigenic potential were injected
contralaterally into the same mouse, pro-angiogenic cytokines
secreted by human luminal breast cancer cells have been shown to
mobilize pro-angiogenic vascular endothelial growth factor receptor
2 (VEGFR2)+ bone marrow-derived cells into distal tumors to
promote angiogenesis (Kuznetsov et al., 2012). However, systemic
influences can also be anti-metastatic. Using human prostate and
breast cancer cells, and a combination of spontaneous and
experimental metastasis models, an earlier study suggested that the
presence of a primary tumor can inhibit metastatic seeding. This was
mediated through secretion of prosaposin (a precursor of saposins,
which function as cofactors for sphingolipid hydrolases), which
stimulates expression of the angiogenic factor thrombospondin-1 in
lung stromal cells (Kang et al., 2009). Thus, models that faithfully
mimic systemic influences in patients are required to better
understand the influence of secreted factors on metastasis.
Immune rejection is a key factor that limits the efficiency of tumor
engraftment in immune-competent preclinical models, even when
the tumor and host are both from the same syngeneic background
(Dunn et al., 2006). It is probably not surprising that immune
suppression generated by established tumors enhances engraftment
efficiency of subsequent (secondary) tumors (Mullen et al., 1985;
Reilly et al., 2000). Careful experiment design is essential to study
tumor-tumor and tumor-host interaction in these models.
Role of epithelial-to-mesenchymal transition in metastasis
Epithelial-to-mesenchymal transition (EMT) (see Glossary, Box 1)
is a developmental program that occurs during embryogenesis
(Thiery et al., 2009). It involves the loss of cell-cell adhesions,
apical-basal polarity and the conversion to a mesenchymal
phenotype that is typified by increased motility and invasiveness
and plays a role in the invasion of tumor cells, an early event in the
metastatic cascade (Valastyan and Weinberg, 2011). It is tightly
controlled by a number of pathways that activate the EMT
transcription factors Snail, Slug, Twist, Zeb1 and Zeb2 (Thiery
et al., 2009). However, there is debate concerning the extent to
which EMT contributes to the different stages of the metastatic
cascade, much of which has arisen from difficulties in
demonstrating that mesenchymal cells persist in metastatic lesions
(Lambert et al., 2017; Yeung and Yang, 2017). This is confounded
by the inherent plasticity exhibited by tumor cells and the
reversibility of the EMT program. Since the use of Cre
recombinase technology has become more prevalent, the
opportunity to study EMT in mouse models and address these
issues has advanced greatly. Prior to this, GEMMs to address the
causal connection between EMT and metastasis implicated in
in vitro studies were lacking.
Utilizing Cre recombinase to perform lineage-tracing
experiments has provided useful insights into the contribution of
EMT to the metastatic process (Fig. 3). One such study involved the
widely used KPC model. In these mice, EMT was identified in
premalignant lesions, and the process was found to be associated
with invasion of the surrounding basement membrane (Rhim et al.,
2012). In addition, inflammation enhanced EMT and entry of tumor
cells into the circulation. However, using the same KPC model,
direct involvement of EMT in the metastatic process was not
supported; conditional deletion of Snai1 or Twist1, the genes that
encode Snail and Twist, respectively, in the primary tumor resulted
in a reduced number of cells undergoing EMT, but this had no
impact on the metastatic spread (Zheng et al., 2015). More recently,
it was shown that loss of Zeb1 in the KPC model is sufficient to
significantly reduce metastatic spread (Krebs et al., 2017). This
highlights the specificity and lack of redundancy between EMT
transcription factors in controlling metastatic spread in this model.
Using mammary tumor models driven by MMTV-PyMT or
human epidermal growth factor receptor 2 (HER2) oncogenes,
Fischer and colleagues also established that EMT and metastasis
might not be as intricately linked as first thought (Fischer et al.,
2015). By using a mesenchymal-specific (Fsp1) promoter to drive
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Cre recombinase-dependent expression of a green fluorescent
protein (GFP) reporter, they observed no enrichment of tumor
cells expressing GFP in the metastatic site, and thus no indication of
an EMT, although there was an enrichment of GFP-expressing
CTCs. A key limitation of this study is the reliance on a single
‘EMT-associated’ promoter to drive the Cre recombinase, as EMT
is controlled and characterized by a plethora of transcriptional
changes. In addition, it does not address the inherent plasticity and
reversibility within the system: EMT does not represent an on-off
switch but is a continuumwith many cells expressing both epithelial
and mesenchymal markers at a given time. Indeed, in a model of
HER2-driven mammary cancer, early dissemination of tumor cells
was associated with a partial EMT, wherein some epithelial cell
properties were retained (Harper et al., 2016).
The use of intra-vital imaging has helped unravel the
complexities associated with tumor cell plasticity and metastatic
spread. In the MMTV-PyMT mammary tumor model, Beerling and
colleagues used a fluorescent epithelial marker (E-cadherin-CFP)
combined with intra-vital imaging to show that EMT is a reversible,
plastic process and that mesenchymal cells that reach secondary
sites can rapidly regain an epithelial phenotype (Beerling et al.,
2016). In contrast with many other studies, it was possible to
demonstrate this plasticity in vivo without experimental modulation
of genes commonly thought to regulate EMT. Models that are able
to accurately recapitulate the metastatic cascade without
experimental gene modulation are key tools in uncovering the
events involved, but in a way that reflects in situ processes as closely
as possible. The use of lineage tracing to assess the contribution of
EMT to metastasis has the potential to help uncover the gene
signature of cells that are able to colonize secondary sites.
Unraveling the polyclonal nature of metastasis
The increasing use of deep-sequencing analysis has helped
elucidate the evolutionary history of metastatic lesions and has
shed light on whether metastatic dissemination follows a linear or
parallel model (Turajlic and Swanton, 2016). Evidence from a
HER2-driven mouse mammary tumor model supports a parallel
model of evolution and also highlights the importance of mouse
models in demonstrating that early disseminated tumor cells are
critical to the formation of metastatic lesions (Hosseini et al., 2016).
Lineage tracing of CTCs and clusters of CTCs has also proven
invaluable in the investigation of the origins of these clusters and
single cells. By using a convertible double-fluorescent mammary
tumor model, ROSAmT/mG; MMTV-PyMT, from which organoids
(see Glossary, Box 1) were injected into the mammary fat pad of
nonfluorescent hosts, Cheung et al. (2016) evidenced the polyclonal
origin of a lesion in the lung, showing that it contained at least two
separate clones based on the fluorescent reporters present. They
found multicolored cell clusters at all stages of the metastatic
cascade, including local disseminated and CTC clusters. The
advent of Brainbow-2.1 (Livet et al., 2007) has allowed the
detailed tracing of multiple cells by utilizing Cre recombinase and
the stochastic expression of four fluorescent proteins from
multiple copies of a single transgene, which can generate up to
90 distinguishable colors when multiple copies of Brainbow-2.1
are present per cell, due to the differential expression of each
transgene (Fig. 3). By combining the transgene with Cre
recombinase placed under tissue-specific promoters, it will be
possible to more fully assess the clonal heterogeneity of a
metastatic lesion using imaging alone (Fig. 3) or in combination
with deep-sequencing techniques. One such example of this is
Prorainbow, a novel fluorescently labeled mouse strain (PB-Cre4;
Pkd1lox/lox; Ptenlox/lox; CMV-XFP/+) that can be used to model
prostate cancer (Fang et al., 2015). Although this model has not
yet been used to look at the metastatic process, initial
characterization indicates that it is an extremely promising
advance in technology to allow assessment of metastatic
colonization in many different mouse models.
A B 
Fig. 3. Lineage tracing allows identification of the clonal nature of metastatic lesions. (A) The Brainbow-2.1 construct contains two tandem invertible DNA
segments, each flanked by loxP sequences (indicated with black arrowheads). Inversion (i-iii) and excision (iv,v) recombination events create four expression
possibilities, with the fluorescent protein that follows the promoter being uniquely expressed. Expression of the different fluorescent proteins at different ratios
within each cell provides a unique color combination for each cell. Adapted from Livet et al. (2007), with permission from Macmillan Publishers Ltd. (B) Cre-
mediated recombination during primary tumorigenesis allows identification of metastatic lesions of a single color, indicating derivation from single cells or clusters
from a single cell, or multicolored cell clusters consisting of many different colored cells.
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Arrest, extravasation and colonization at distant organs
Experimental metastasis assays have illustrated that multiple stromal
components can be hijacked by tumor cells in the process of
metastatic seeding, as detailed below. Platelets play an important
role in facilitating metastatic dissemination. In addition to protecting
cells in the bloodstream from natural killer (NK) cells, interaction of
platelet integrins with collagen at specific regions of the
endothelium may help tumor cell adherence at secondary organs
and determine the site of metastatic tumor cell extravasation (Gay
and Felding-Habermann, 2011; Ruggeri and Mendolicchio, 2007).
A recent study identified that platelets promote tumor cell
extravasation through adenosine triphosphate (ATP)-dependent
activation of the endothelial P2Y2 receptor, which opens the
vessel barrier to enable tumor cell extravasation and metastatic
seeding (Schumacher et al., 2013). This was identified by utilizing
both spontaneous and experimental metastasis models in syngeneic
C57BL/6J mice. The utility of experimental metastasis models in
studying these early events when tumor cells first reach the
metastatic site was further highlighted by another group, who were
able to show that metastatic seeding is promoted by coagulation
pathways, in particular tissue factor (TF). By imaging myeloid-
tumor cell interactions within the lung following intravenous
injection of tumor cells, they demonstrated that TF-induced platelet
clots attract recruitment of bone marrow-derived macrophages to
support the survival of metastatic melanoma cells and inhibit NK
cell-mediated destruction of micrometastases in the lung (Gil-
Bernabe et al., 2012).
Using both spontaneous and experimental lung metastasis
models of breast cancer, a distinct population of metastasis-
associated macrophages (MAMs) has been characterized in the
target organ (lung). Depletion of these MAMs using transgenic
CD11b-diphtheria toxin receptor (DTR) mice significantly reduces
metastatic seeding and persistent growth of breast cancer cells (Qian
et al., 2011). One caveat of this approach is that administration of
diphtheria toxin to CD11b-DTR mice selectively kills CD11b-
expressing monocytes as well as macrophages (Stoneman et al.,
2007). However, ex vivo intact lung imaging in the same model
revealed that macrophages (and not monocytes) directly contact the
extravasating tumor cells, and depletion of these macrophages
significantly reduces the number of tumor cells that complete
extravasation (Qian et al., 2009).
Adhesion signaling also plays an important role in the survival of
tumor cells within the metastatic niche. Using an innovative method
of experimental bone metastasis in which breast cancer cells were
injected into the iliac artery of mice (both allograft and xenograft
models), Wang et al. (2015) showed that bone seeding of multiple
human and murine breast cancer cells is dependent on heterotypic
adherens junctions between cancer cells and osteogenic cells.
Thus, a number of models and experimental approaches have
demonstrated the importance of the interaction of tumor cells with
stromal cells in the metastatic niche that is required to support the
outgrowth of secondary tumors.
Dormancy in the metastatic niche
Metastases can arise fromDTCsmany years after the initial treatment
and/or surgical removal of the primary tumor. This is because at the
time of diagnosis, metastatic spread has already occurred but the
resulting DTCs have entered a state of quiescence (Sosa et al., 2014).
Thesemetastases may be resistant to current therapies that are directed
at proliferating cells; therefore, targeting dormant DTCs or preventing
their reactivation from dormancy may be of clinical benefit. The
factors that control tumor dormancy are poorly understood, but using
a spontaneousmodel of breast cancer metastasis, DTCswere found to
reside on the microvasculature of different organs and subsequent in
vitro experiments demonstrated that distinct endothelial niches can
induce dormancy through the secretion of thrombospondin-1 (Ghajar
et al., 2013). A gain-of-function screen in an allograft model ofmouse
mammary carcinoma identified the bone morphogenetic protein
(BMP) inhibitor Coco as a mediator of DTC reactivation (Gao et al.,
2012). Coco stimulated the proliferation of DTC in the lungs through
induction of a discrete gene expression signature that was associated
with relapse to the lung but not to other organs where BMP is not
active. This highlights the organ specificity of signals that control
reactivation of DTCs in the metastatic niche. Bragado et al. (2013)
provided further support to this by tracing spontaneous DTCs
following subcutaneous transplantation of a head and neck squamous
cell carcinoma cell line. They showed that transforming growth
factor beta 2 (TGFβ2) signaling in the bone marrow initiates tumor
dormancy, while the low levels of TGFβ2 signaling found in the
lungs prevented long-term dormancy, resulting in outgrowth of
metastatic lesions (Bragado et al., 2013). These studies support the
concept of dormancy-permissive and -restrictive microenvironments
that determine whether DTCs divide or remain quiescent. The
collection and analysis of CTCs and DTCs from patients at different
stages of the metastatic journey will provide important information
and clinical validation of the functional regulators linked to the
emergence of overt metastatic disease. This should provide an
iterative framework for the further refinement of mouse models.
Therapeutics and translation
Although mouse models have been invaluable in enhancing our
understanding of the biology that drives the metastatic cascade, their
utility as preclinical drug development tools is less well defined.
The approval rate of oncology drugs remains poor, with recent
research indicating that only 7.5% of oncology drugs that entered
phase I clinical development, and 33.2% of drugs that entered phase
III trials, were eventually approved (Toniatti et al., 2014). This
highlights the need for more predictive and improved preclinical
mouse models. The majority of preclinical studies that support
clinical evaluation rely on the use of established cell lines grown
ectopically in immune-deficient mice. These cell lines show limited
tumor heterogeneity, and combined with the lack of appropriate
human stroma and an intact immune system (Table 1), this
contributes to the poor clinical predictivity of these models (Singh
and Ferrara, 2012; Toniatti et al., 2014). In most studies, regression
of primary tumor growth is used as an endpoint and no
consideration is given to effects on metastatic disease (in most
cases metastatic disease is not even modeled). By contrast, the
majority of early clinical trials will involve patients with advanced
metastatic disease and as the genetic and epigenetic landscape of
metastases differ from the primary tumor, which is reflected in the
response to treatment, identifying the most effective way to model
this will have an impact on drug development programs. The ability
to model this in preclinical models is challenging, but the resistance
of metastatic disease to current therapies and the realization that
>90% of cancer-related mortality is due to metastatic disease
progression highlights the need for new approaches to be
considered. In addition to developing improved models, a better
understanding of how best to implement currently available models
could provide benefits (Francia et al., 2011; Steeg, 2016). For
example, experimental metastasis models have been used widely,
but what needs to be considered is the cell population that is being
targeted in these models. Do they reflect the outgrowth of latent
tumor cells or the subsequent growth of macrometastatic lesions?
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Such nuances are currently difficult to address in most models and
are not often considered when carrying out drug intervention
studies.
Despite the limitations associated with the use of established cell
lines in immune-deficient animals, they can provide important
insights into the potential clinical activity of drugs, for which
differential responses to therapies have been reported between
primary and metastatic lesions, thus reflecting what is seen in the
clinic (Francia et al., 2011). Another important consideration is how
closely we can recapitulate clinically relevant intervention
strategies. Surgical removal of the primary tumor followed by
adjuvant treatment to prevent recurrence is widely used in clinical
practice. Spontaneous metastasis models that utilize cell lines
(xenograft, allograft) are particularly amenable to modeling
adjuvant treatments, although they are limited to a few models
where the primary tumor can be easily resected (e.g. Cruz-Munoz
et al., 2008; Ebos et al., 2009). Although these experiments can be
technically challenging and time-consuming, they have provided
useful insight into the activity of drugs in the clinical setting. For
example, studies with transplantable models have helped to unravel
the effects of anti-angiogenic therapies in the adjuvant setting
(Kerbel et al., 2013) and shed light on the possible mechanisms
responsible for the disappointing results of recent Phase III clinical
trials in metastatic breast cancer (Bridgeman et al., 2017).
The benefits of GEMMs in generating tumors that develop in the
organ of origin (autochthonous) in immune competent hosts has led
to their adoption for preclinical assessment of drug response and
mechanisms of resistance (Gopinathan et al., 2015; van Miltenburg
and Jonkers, 2012). GEMMs are very useful for studying early and
late stages of disease, and studies showing the clinical predictivity
of lung and pancreatic cancer GEMMs to chemotherapy are
encouraging (Singh et al., 2010), but this needs to be more widely
validated in other models and the impact on metastatic disease
evaluated. These models are often limited by growth of the primary
tumor, which necessitates cull of the animals and thus true effects on
metastasis-associated survival cannot be monitored (Karim et al.,
2013). Most GEMMs are not amenable to resection of the primary
tumor and thus dissecting effects on primary tumor growth from
specific effects on metastatic disease are complicated, as neoadjuvant
and adjuvant studies cannot be carried out although excision of
primary pancreatic tumors in the KPC model is being trialed
(Gopinathan et al., 2015). In addition, in the context of mammary
tumors, the development of transplantation models in which
fragments of tumors are re-implanted into recipient mice allows
resection of the primary tumor and the subsequent monitoring of
metastatic spread. This reduces the latency and variability in
metastatic dissemination making this approach more amenable to
drug studies. This opens up the possibility of using these models for
testing adjuvant therapies and importantly for assessing the potential
of new immunotherapies (Coffelt et al., 2015).
PDX models are also predicted to be a major advance in
preclinical testing platforms as they recapitulate the tumor
heterogeneity that plays such an important role in tumor biology,
including response to therapy. A number of therapeutic studies have
demonstrated their value in linking response with genetic alterations
and identifying mechanisms of resistance and biomarkers, while use
of humanized mice recipients will further enhance their value as we
look at the potential for testing immunotherapies (Byrne et al.,
2017). However, the cost and length of time required to conduct
studies in PDX models is restrictive and, as yet, their utility in
assessing effects on metastatic spread is not clear. Although
spontaneous metastases do develop, this is limited to a relatively
small number of PDX models, with orthotopic injection of tumor
fragments being more successful in modeling metastatic spread
(Pompili et al., 2016). Moreover, the asynchronous development of
metastatic disease in these models would require large cohorts of
animals, which further increases the cost of such studies. Generation
of PDX from primary tumors and metastatic sites from the same
patient that can be transplanted orthotopically would allow direct
evaluation of drugs in the metastatic setting.
The increasing use of imaging modalities that allow noninvasive
longitudinal monitoring of metastases will help more accurate
detection and quantification of metastatic disease in deep tissue
sites. This technology is thus likely to enhance the usability of
GEMMs and PDXs. Recent advances in preclinical magnetic
resonance imaging (MRI), computed tomography (CT), positron
emission tomography (PET) and single-photon emission computed
tomography (SPECT) are showing promise (Fleten et al., 2017;
Marien et al., 2017; Sanches et al., 2015; Taromi et al., 2016).
A greater understanding of the pathways that drive metastatic
spread and what is achievable in the clinical setting gives hope that
anti-metastatic therapies will be viable in the future. For example,
targeting metastatic colonization, which is often the rate-limiting
step in the metastatic cascade holds great potential, but it will be
important to provide robust preclinical evidence of activity in
appropriate animal models that accurately reflect the clinical
scenario in which the therapy will ultimately be tested in. Careful
thought to clinical trial design with appropriate primary endpoints is
also essential.
Future outlook
Mouse models have been essential in advancing our understanding of
the biological processes that drive tumor progression. However,
metastatic cancer remains the main cause of cancer-related deaths,
with new treatments desperately needed. Increasing our understanding
of what drives metastatic spread is key to achieving this goal. This will
require the further development and refinement of mouse models to
more faithfully mimic human disease and progression.
A number of technological advances have allowed the further
development of GEMMs. These include combined use of the Cre-
loxP and Flp-FRT systems (Schönhuber et al., 2014) that allow
sequential activation or inactivation of genes, thereby enabling
human disease progression to be mimicked more closely, which
may provide more representative metastatic progression models.
This also opens up the possibility of targeting both tumor and
stromal cells in the samemodel, which is an important consideration
when studying metastatic progression. In addition, the CRISPR/
Cas9 gene editing system (see Glossary, Box 1) has been used to
successfully introduce targeted mutations in GEMMs, enabling
more rapid validation and characterization of putative cancer genes
that are being uncovered by the large-scale sequencing efforts
currently underway using human tissue samples (Annunziato et al.,
2016; Chiou et al., 2015; Sánchez-Rivera et al., 2014; Weber et al.,
2015). It is hoped that this will help in the design of better GEMMs
that more readily recapitulate the metastatic tropism seen in human
disease. The development of humanized mouse models that
incorporate human-derived stromal components, including CAFs
and immune cell populations, will help with regards to metastasis to
particular sites (Shultz et al., 2012). For example, human bone discs
and engineered human bone environments have been used to model
bone metastases (Holen et al., 2015; Wright et al., 2016). RNA
interference and CRISPR/Cas9 screens have been used to identify
metastatic drivers in in vivo transplantation models (Chen et al.,
2015; Murugaesu et al., 2014); the validation of these and
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improvements in such screening approaches will help in the
development of future GEMMs.
The design of more biologically relevant in vitro models that try
to recapitulate the complexity of the tumor microenvironment is a
major area of ongoing research. Models include co-culture of tumor
cells with different stromal cell types and 3D engineered matrixes,
with developments in 3D bioprinting and microfluidics platforms
having the potential to significantly impact on the design and
reconstruction of the complex tumor microenvironment (Albritton
andMiller, 2017). Coupled with the use of high-resolution real-time
imaging, microfluidics devices have been used to study different
components of the metastatic cascade such as intra- and
extravasation (Jeon et al., 2015; Zervantonakis et al., 2012). The
design of these models could be geared towards addressing specific
questions about the biology that drives metastatic behavior.
Importantly, such in vitro models have the potential to be used as
drug screening platforms and could guide the preclinical testing of
new agents in mouse models.
Advances in intra-vital imaging have shown great potential for
elucidation of the close interplay between tumor and host cells
(Cuccarese et al., 2017; Hawkins et al., 2016; Headley et al., 2016;
Lee et al., 2015; Szulczewski et al., 2016), and fundamental aspects
of the metastatic process. For example, use of a Cre recombinase-
driven reporter system has allowed the visualization of extracellular
vesicle exchange between tumor cells and has provided further
insight into the biological consequences and potential impact on
metastatic potential (Zomer et al., 2015). The use of optical
windows to allow imaging in the metastatic niche provides both
spatial and temporal information on the behavior of cancer cells;
another major advance (Entenberg et al., 2015; Headley et al., 2016;
Ritsma et al., 2012; Rodriguez-Tirado et al., 2016). The ability of
such imaging approaches to shed light on the localization
and activity of drugs within the tumor microenvironment
(Dubach et al., 2016; Junankar et al., 2015; Tipping et al., 2016)
also provides a more sophisticated platform for evaluation of new
therapies.
Although much is known about the biological pathways that
control the individual steps in the metastatic cascade, a number
of important questions remain. Uncovering the underlying
mechanisms that govern the enormous diversity in the onset and
target organs affected in patients and identifying whether there are
common mechanisms at play will be important. In addition,
understanding the fundamental differences between primary and
secondary tumors and the drivers of metastatic colonization is
essential to identifying strategies for targeting metastatic disease,
and would have a major impact on the survival of cancer patients.
The technological advances in the generation of mouse models that
better mimic human disease, combined with advances in imaging,
will allow for the translation of such research into meaningful
treatments.
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